Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1834020 | 0.81 | MAPT (0.46) | CYP1A2CYP2C19LMNARAB9AHTT | |
| SCHEMBL1834024 | 0.81 | MAPT (0.46) | CYP1A2CYP2C19LMNARAB9AHTT | |
| SCHEMBL3606682 | 0.81 | MAPT (0.46) | CYP1A2CYP2C19LMNARAB9AHTT | |
| SCHEMBL1760391 | 0.81 | ALDH1A1 (0.38) | KMT2ALMNAHTTL3MBTL1BRD4 | |
| SCHEMBL3619842 | 0.81 | ALDH1A1 (0.38) | KMT2ALMNAHTTL3MBTL1BRD4 | |
| SCHEMBL1760389 | 0.81 | ALDH1A1 (0.38) | KMT2ALMNAHTTL3MBTL1BRD4 | |
| SCHEMBL16545983 | 0.80 | SPHK1 (0.41) | KMT2ALMNABRD4GPR119 | |
| SCHEMBL17819587 | 0.80 | SPHK1 (0.41) | KMT2ALMNABRD4GPR119 | |
| SCHEMBL6732088 | 0.76 | GPR119 (0.40) | CYP1A2CYP2C19RAB9ABRD4TSHR | |
| SCHEMBL1834016 | 0.75 | GPR119 (0.40) | CYP1A2CYP2C19RAB9ABRD4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142975-A1 | Beta disubstituted metalloprotease inhibitors | THE PROCTER &GAMBLE COMPANY | 2004-07-22 | — | — | US | disclosed |
| US-6696456-B1 | CARBOCYCLIC ACIDS AND SALTS SUCH AS (2S,3R)-3-ETHYLSULFANYL-2-(4'-FLUORO-BIPHENYL-4-SULFONYLAMINO)-3- PHENYLPROPIONIC ACID, USED AS METALLOENZYME ANTAGONISTS FOR THE PROPHYLAXIS OF DEGENERATIVE JOINT DISEASE AND AS WOUND HEALING AGENTS | THE PROCTER & GAMBLE COMPANY | 2004-02-24 | — | — | US | disclosed |
| EP-1224171-A1 | BETA DISUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001027084-A1 | BETA DISUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142975-A1 | Beta disubstituted metalloprotease inhibitors | ADAM17, ADAM9, SI | CYP1A2 248/4885CYP2C19 321/4885KMT2A 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.